Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors
نویسندگان
چکیده
منابع مشابه
Amplification of c-erbB-2 and aggressive human breast tumors?
well as allelic deletions ofgenes on chromosomes 11 or 13 (9, 10). The frequency and level of amplification of c-myc and c-erbB-2 proto-oncogenes vary between different groups of patients studied by different laboratories. Amplification of c-erbB-2 was reported in 10, 16, 18, and 40% of breast tumors from different groups of patients (2, 5-8). In one study this proto-oncogene was suggested as a...
متن کاملgene expression profiling for cancer targeted therapy
background : lung cancer is still the leading cause of cancer- related deaths and most of themâ are normally diagnosed in late stages, so there is an urgent need to establish reliable tools for the identification at early stages of the disease. in this study, we use an eleven gene signature test to examine lung biopsy specimens for diagnostic, prognostic & therapeutic purposes. methods : bronc...
متن کاملDevelopmental trends in targeted radionuclide therapy of neuroendocrine tumors
Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms including carcinoids, pancreatic neuroendocrine tumors, pituitary tumors, medullary thyroid carcinoma and phaeochromocytomas. The symptoms and the outcome of NETs differ considerably between patients depending on several factors. By labelling tracers with a radioisotope, the tracer acts as a ...
متن کاملTreatment of aggressive prolactinoma with temozolomide
Rationale: Aggressive pituitary adenomas and pituitary carcinomas are rare and demand multiple treatment strategies. Temozolomide, an orally active alkylating chemotherapeutic agent, has recently been recommended as a salvage medication for refractory pituitary adenomas or carcinomas. Patient concerns: A 17-year-old male presenting with aggressive prolactinoma that continued to progress despite...
متن کاملBrain metastases and testicular tumors: need for aggressive therapy.
In late 1974, the combination of cisplatin, vinblastine, and bleomycin (PVB) became the standard chemotherapeutic regimen for treatment of disseminated nonseminomatous germ cell testicular tumors (NSGCT) at Indiana University Hospital. A retrospective analysis of the treatment records of all patients with brain metastases from NSGCTs treated at the Indiana University Radiation Oncology Departme...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Endocrine
سال: 2013
ISSN: 1355-008X,1559-0100
DOI: 10.1007/s12020-013-0093-x